Archive for the ‘ExL Events News’ Category
ExL’s Value-Based Strategies for Reimbursement and Formulary Success Conference Producer, Mercy Lister, had the opportunity to sit down and discuss some of the issues and challenges facing the industry with the event’s chair, Melissa L. Paige, Oncology Patient Access Principal Coordination at the University of Virginia Health System, NCI-Designated Emily Couric Clinical Cancer Center. See excerpts from the Q&A session below.
Q: How do you collaborate with payers and pharma to get access to the right product at the right time for the right patient?
A: Prior to any product launch, we seek…
The entire ExL Events team is excited to announce that the 7th Digital Marketing for Medical Devices West conference is taking place April 23–25, 2018 in San Francisco!
The 7th Digital Marketing for Medical Devices West conference is built on a foundation providing device marketers with seven years of informative, relevant content and is attended by marketers representing device organizations of all sizes. This conference is designed to provide you with in-depth, tactical presentations that supply you with a roadmap for implementing similar programming at your organization and insights into some of the leading marketing trends impacting the industry…
The 13th Pharmaceutical Meeting Professionals Summit is coming up in just a few weeks on November 6–7 in Philadelphia. Over 60% of the current audience represents meeting planners from well over 100 different companies in various industries. Check out this experienced group ready to engage, collaborate, and innovate to optimize medical meeting management.
ALTOUR Meetings & Incentives
American Audio Visual
American Express Meetings & Events
Andavo Meetings & Incentives
Ashfield Meetings & Events
Beverly Hills Conference & Visitors Bureau
Big Sky Resort
Boehringer Ingelheim Pharmaceuticals
Cheshire Audio Visual
Cornerstone Meetings & Events
The Innovative Regulatory Pathways Summit, taking place January 29–30 in Arlington, VA, is the only regulatory affairs conference dedicated to global strategies for expediting drug development.
Download our brochure here to review the sessions dedicated to how breakthrough therapy designations fit into global development pipelines.
Receiving a breakthrough therapy designation has a huge impact on clinical development, which is why Joseph A. Sliman, M.D., MPH, Chief Medical Officer, at Synthetic Biologics, will discuss the implications of receiving a breakthrough therapy designation on clinical trial design for narrow populations.
A manufacturing plan that is harmonized with expedited clinical develop…
Before she takes that podium at our 4th Rx-to-OTC Switch Summit, Susan B. Levy Consulting’s Founder and Principal, Susan Levy, sat down with ExL to discuss the OTC market and pre-launch preparation. Take a look here:
You’ve been involved in ExL Events’ Rx-to-OTC Summit since 2014 — what has changed since then and what brings you back?
Since 2014, we’ve seen additional switches in existing OTC categories, including Flonase, Nexium, Rhinocort, and Xyzal. Some of these switches have been more successful than others. We’ve also seen two Advisory Committee Meetings. Singulair failed to…
Industry Leaders From Pfizer, Merck and Pacira Share Insights at the Value-Based Reimbursement Event!
The methodical challenges faced by market access professionals can vastly differ by therapeutic area, size of the organization, and the number of resources available to them. Cookie-cutter solutions cannot address the unique challenges faced by a company. It is critical that the education available to market access professionals meets the varying needs of the industry. Don’t worry — leaders from Pfizer, Merck, Pacira and more share insights at our Value-Based Reimbursement event.
The speaking faculty at ExL’s Value-Based Strategies for Reimbursement and Formulary Success conference consists of executives from pharmaceutical…
ExL’s premier co-located event series, taking place October 26–27 in Boston, features three conferences, 50+ speakers, and two days of shared networking with 150+ industry executives. These three conferences will bring together experts from nonprofits, NGOs, academia, pharmaceutical companies and biotechs to discuss the balance between social equity and business goals.
The Non-Profit/NGO/Academic rate is 40% off the standard registration price for all of the below conferences…
* To receive this discount, please use Discount Code 2017NP
View the agenda…
Neglected Tropical Diseases Forum: GSK, Merck, and More Discuss Strategic Partnerships in Global Health Programs
The Neglected Tropical Diseases Forum, taking place on October 26–27, 2017 in Boston, is the premier event for building strategic partnerships to support global health programs across the biomedical landscape. Attendees will hear case studies about strategies that support sustained funding and help overcome clinical development and regulatory challenges associated with NTD treatments and diagnostics.
Review all of the session topics and presentations in our agenda here.
Michael Eichberg, Director, Strategic Alliances, Merck, will be discussing experiences with synergistic partnerships to combat the Ebola outbreak.
Shelly O’Donovan, Former…
The Innovative Regulatory Pathways Summit is taking place January 29–30, 2018 in Arlington, VA. This intimate summit will bring together leading regulatory experts and senior-level executives to discuss regulatory strategies to expedite drug development in the U.S., EU, and Japan. Download the brochure here to review the sessions and speakers featured at this event.
Breakthrough therapy designations and other expedited pathways encourage sponsors to increase communication and collaboration with the FDA. Expedited drug development options are also available globally in ICH countries…
ExL Events is excited to announce the Cannabis Partnerships Congress, taking place March 12–13, 2018 in San Francisco, CA! The Cannabis Congress is an educational forum designed to bring all stakeholders involved in the cannabis-based scientific, medicinal, governmental, and product development to fortify the therapies in a collaborative environment.
Despite recent changes in state policy, and with the increasing rate of cannabis use and its implications for health, the government has yet to legalize cannabis. With the continued enforcement of restrictive policies and regulations on research into the health benefits, it is important…
From The Blog
- Commercial Strategy
- Content Marketing
- Data Management
- Digital Marketing
- Drug Safety
- Emerging Markets
- ExL Events News
- Medical Devices
- Medical Education
- Meeting Planning
- Patient Engagement
- Public/Government Relations
- Regulatory Affairs